1775 related articles for article (PubMed ID: 15132713)
1. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.
Wilkinson DG; Francis PT; Schwam E; Payne-Parrish J
Drugs Aging; 2004; 21(7):453-78. PubMed ID: 15132713
[TBL] [Abstract][Full Text] [Related]
2. Cholinesterase inhibitors for Alzheimer's disease.
Birks J
Cochrane Database Syst Rev; 2006 Jan; 2006(1):CD005593. PubMed ID: 16437532
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors.
Jann MW; Shirley KL; Small GW
Clin Pharmacokinet; 2002; 41(10):719-39. PubMed ID: 12162759
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease.
Imbimbo BP
CNS Drugs; 2001; 15(5):375-90. PubMed ID: 11475943
[TBL] [Abstract][Full Text] [Related]
5. Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology.
Nordberg A; Svensson AL
Drug Saf; 1998 Dec; 19(6):465-80. PubMed ID: 9880090
[TBL] [Abstract][Full Text] [Related]
6. Chronic treatment of old rats with donepezil or galantamine: effects on memory, hippocampal plasticity and nicotinic receptors.
Barnes CA; Meltzer J; Houston F; Orr G; McGann K; Wenk GL
Neuroscience; 2000; 99(1):17-23. PubMed ID: 10924948
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease.
Noetzli M; Eap CB
Clin Pharmacokinet; 2013 Apr; 52(4):225-41. PubMed ID: 23408070
[TBL] [Abstract][Full Text] [Related]
8. The new cholinesterase inhibitors for Alzheimer's disease, Part 2: illustrating their mechanisms of action.
Stahl SM
J Clin Psychiatry; 2000 Nov; 61(11):813-4. PubMed ID: 11105732
[No Abstract] [Full Text] [Related]
9. [Development of therapies for Alzheimer's disease based on cholinergic hypothesis-status quo and future directions].
Shimohama S
Rinsho Shinkeigaku; 2013; 53(11):1036-8. PubMed ID: 24291871
[TBL] [Abstract][Full Text] [Related]
10. Nicotinic cholinergic modulation: galantamine as a prototype.
Woodruff-Pak DS; Lander C; Geerts H
CNS Drug Rev; 2002; 8(4):405-26. PubMed ID: 12481195
[TBL] [Abstract][Full Text] [Related]
11. Unequal neuroprotection afforded by the acetylcholinesterase inhibitors galantamine, donepezil, and rivastigmine in SH-SY5Y neuroblastoma cells: role of nicotinic receptors.
Arias E; Gallego-Sandín S; Villarroya M; García AG; López MG
J Pharmacol Exp Ther; 2005 Dec; 315(3):1346-53. PubMed ID: 16144975
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of purinergic neurotransmission by galantamine and other acetylcholinesterase inhibitors in the rat vas deferens.
Caricati-Neto A; D'angelo LC; Reuter H; Hyppolito Jurkiewicz N; Garcia AG; Jurkiewicz A
Eur J Pharmacol; 2004 Oct; 503(1-3):191-201. PubMed ID: 15496314
[TBL] [Abstract][Full Text] [Related]
13. The new cholinesterase inhibitors for Alzheimer's disease, Part 1: their similarities are different.
Stahl SM
J Clin Psychiatry; 2000 Oct; 61(10):710-1. PubMed ID: 11078030
[TBL] [Abstract][Full Text] [Related]
14. Switching cholinesterase inhibitors in patients with Alzheimer's disease.
Emre M
Int J Clin Pract Suppl; 2002 Jun; (127):64-72. PubMed ID: 12139369
[TBL] [Abstract][Full Text] [Related]
15. Acetylcholinesterase inhibition in Alzheimer's Disease.
Ibach B; Haen E
Curr Pharm Des; 2004; 10(3):231-51. PubMed ID: 14754384
[TBL] [Abstract][Full Text] [Related]
16. An update on the pharmacology of galantamine.
Villarroya M; García AG; Marco-Contelles J; López MG
Expert Opin Investig Drugs; 2007 Dec; 16(12):1987-98. PubMed ID: 18042006
[TBL] [Abstract][Full Text] [Related]
17. Pharmacology of selective acetylcholinesterase inhibitors: implications for use in Alzheimer's disease.
Liston DR; Nielsen JA; Villalobos A; Chapin D; Jones SB; Hubbard ST; Shalaby IA; Ramirez A; Nason D; White WF
Eur J Pharmacol; 2004 Feb; 486(1):9-17. PubMed ID: 14751402
[TBL] [Abstract][Full Text] [Related]
18. Understanding and managing behavioural symptoms in Alzheimer's disease and related dementias: focus on rivastigmine.
Robert P
Curr Med Res Opin; 2002; 18(3):156-71. PubMed ID: 12094826
[TBL] [Abstract][Full Text] [Related]
19. BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors.
Chianella C; Gragnaniello D; Maisano Delser P; Visentini MF; Sette E; Tola MR; Barbujani G; Fuselli S
Eur J Clin Pharmacol; 2011 Nov; 67(11):1147-57. PubMed ID: 21630031
[TBL] [Abstract][Full Text] [Related]
20. Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action.
Poirier J
Int J Clin Pract Suppl; 2002 Jun; (127):6-19. PubMed ID: 12139368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]